← Back to patent-cliff list
Opelconazole
Tier C — Watch / tradeOpelconazole
Pulmocide Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP51A1
Indications (approved)：肺曲霉病, Aspergillus infection, 肺脏移植排斥, Chronic obstructive pulmonary disease, Cystic fibrosis, Asthma, Bronchiectasis
Regional status
US
Phase II
2021-11-19
EU
Discontinued
2022-06-14
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Opelconazole?
Approved indications include: 肺曲霉病, Aspergillus infection, 肺脏移植排斥, Chronic obstructive pulmonary disease, Cystic fibrosis, Asthma, Bronchiectasis.
When does the Opelconazole patent expire?
No public expiry year is available for Opelconazole yet; this page updates once verified.
How do I get a quote for Opelconazole intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08